Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Rhea-AI Summary

Innoviva (NASDAQ: INVA), a diversified holding company with a core royalties portfolio and a leading critical care and infectious disease platform, announced its participation in the Citi 2024 Global Healthcare Conference. CEO Pavel Raifeld will join a fireside chat on December 5, 2024, at 8:45 a.m. Eastern Time in Miami, FL. A live webcast of the chat will be available under the 'Events & Presentations' section on Innoviva's website. The webcast will remain accessible for replay for 90 days.

BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Citi 2024 Global Healthcare Conference in Miami, FL on Thursday, December 5, 2024 at 8:45 a.m. Eastern Time.

A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.

About Innoviva

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR^®/BREO^® ELLIPTA^® and ANORO^® ELLIPTA^®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO^® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA^® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA^® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.

ANORO^®, RELVAR^® and BREO^® are trademarks of the GSK group of companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241126615530/en/

Innoviva, Inc.

David Patti

Corporate Communications

(908) 421-5971

david.patti@inva.com

Investors and Media:

Argot Partners

(212) 600-1902

innoviva@argotpartners.com

Source: Innoviva, Inc.

FAQ

When will Innoviva participate in the Citi 2024 Global Healthcare Conference?

Innoviva will participate on December 5, 2024.

What time is Innoviva's fireside chat at the Citi 2024 Global Healthcare Conference?

The fireside chat is scheduled for 8:45 a.m. Eastern Time.

Where can I watch the live webcast of Innoviva's fireside chat?

The live webcast can be accessed under 'Events & Presentations' in the Investor Relations section of Innoviva's website.

How long will the webcast replay be available after the Citi 2024 Global Healthcare Conference?

The webcast will be available for replay for 90 days after the event.